Document:

Amended and Restated Voting Agreement, dated as of June 6, 2002

 Exhibit 4.3 
  

EXECUTION COPY 
  
 ATRICURE, INC. 
  
 AMENDED AND RESTATED VOTING AGREEMENT 
  
 This Amended and Restated Voting Agreement (this “Agreement”) is entered into as of this 6th day of June, 2002, by and among AtriCure, Inc., a Delaware corporation (the “Company”), the undersigned holders of Common Stock of the Company
(collectively, the “Common Stockholders”), the undersigned holders of Series A Preferred Stock of the Company (collectively, the “Series A Stockholders”) and the undersigned purchasers of Series B Preferred Stock of the Company
(collectively, the “Series B Stockholders”). The Common Stockholders, the Series A Stockholders and the Series B Stockholders are collectively referred to herein as the “Stockholders,” with each a “Stockholder.” All
capitalized terms not defined herein shall have the meanings ascribed to such terms in the Series B Convertible Preferred Stock Purchase Agreement of even date herewith (“Purchase Agreement”). 
  
 RECITALS 
  
 WHEREAS, contemporaneously with the execution and delivery of this Agreement, the Series B Stockholders are purchasing
shares of Series B Preferred Stock pursuant to the Purchase Agreement; and 
  
 WHEREAS, as a condition precedent to the investment by the Series B Stockholders, each of the signatories hereto, and any subsequent holder of record who acquires shares from the signatories hereto (except such
persons who acquire such shares pursuant to a public disposition), desires to enter into and agree to be bound by this Agreement, which amends and restates the Voting Agreement, dated as of May 25, 2001, among the Company, the Common Stockholders
and the Series A Stockholders (the “Old Agreement”). 
  
 NOW, THEREFORE, in consideration of the foregoing and the mutual covenants set forth below, the adequacy and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 1. Shares Subject to Agreement. The Stockholders each agree, as to all
of the shares of Common Stock, Series A Preferred Stock and Series B Preferred Stock of the Company that are now held by them and any and all other securities of the Company acquired by them after the date hereof or that may be issued upon
conversion of any of the foregoing securities owned by them, together with any securities issued to the such person upon any exchange, stock split, stock dividend, recapitalization or the like (the “Shares”), that each shall vote all such
Shares in accordance with the provisions of this Agreement. 
  

 2. Obligation to Vote Shares for Specific Nominees. 
  
 (a) Obligation as to Directors. In accordance with
the terms of the Company’s Certificate of Incorporation and Bylaws, until the termination of this Agreement pursuant to Section 5 hereof, each of the Stockholders hereby agrees, at any stockholder meeting, or upon any action by written consent
in lieu of meeting, for the purpose of electing directors, to vote or cause to be voted or act with respect to all of the Shares held by such Stockholder or over which such Stockholder has voting control such that, whether or not cumulative voting
is in effect, the following shall be elected as Company’s Board of Directors: 
  

	 	(i)	with respect to the three (3) Board members to be nominated and elected by the Common Stockholders pursuant to Article IV, Subsection 5(b)(iii) of the Company’s Certificate of
Incorporation, the Common Stockholders agree that: (x) such seats shall be designated by a majority in interest of the then issued and outstanding shares of Common Stock voting as a separate single class; (y) one of such seats shall be that
individual who is then appointed by the Board of Directors to fill the position of Chief Executive Officer of the Company (the “CEO”); and (z) initially, the Common Stockholders hereby designate elect Michael D. Hooven, Norman R. Weldon
and the CEO as members of the Board of Directors; 

  

	 	(ii)	with respect to the two (2) Board members to be nominated and elected by the Series A Stockholders pursuant to Article IV, Subsection 5(b)(i) of the Company’s Certificate of
Incorporation, the Series A Stockholders agree that: (w) such seats shall be designated by a majority in interest of the then issued and outstanding shares of Series A Preferred Stock voting as a separate single class; (x) the Series A Stockholders
will elect as one (1) of such Board members whomever may be designated by Charter Ventures IV, L.P. (“Charter”) from time to time; (y) the Series A Stockholders will elect as one (1) of such Board members whomever may be designated by
Partisan Management Group, Inc. (“Partisan”) from time to time; and (z) initially Charter hereby designates Donald C. Harrison as a member of the Board of Directors and initially Partisan hereby designates Karen P. Robards as a member of
the Board of Directors; 

  

	 	(iii)	 with respect to the two (2) Board members to be nominated and elected by the Series B Stockholders pursuant to Article IV, Subsection 5(b)(ii) of the Company’s
Certificate of Incorporation, the Series B Stockholders agree that: (w) such seats shall be designated by a majority in interest of the then issued and outstanding shares of Series B Preferred Stock voting as a separate single class; (x) the Series
B Stockholders will elect as one (1) of such Board members 

  

 2 

	 	 
whomever may be designated by U.S. Venture Partners VIII, L.P. (“USVP”) from time to time; (y) the Series B Stockholders will elect as one (1) of
such Board members whomever may be designated by Camden Partners, Inc. (“Camden”) from time to time; and (z) initially USVP hereby designates Alan Kaganov as a member of the Board of Directors and initially Camden hereby designates Richard
M. Johnston as a member of the Board of Directors; 

  

	 	(iv)	with respect to the one (1) Board member to be elected by the Stockholders pursuant to Article IV, Subsection 5(b)(iv) of the Company’s Certificate of Incorporation, the
Stockholders agree that such seat shall be held by an individual designated by the other members of the Board of directors, subject to the approval by a majority in interest of the Shares voting together, on an as-converted basis, as a single class
(the “Majority Director”); initially, the Majority Director is hereby designated to be Delos M. Cosgrove, III, and 

  

	 	(v)	any vote taken to remove any director elected pursuant to this Section 2, or to fill any vacancy created by the resignation or death of a director elected pursuant to this Section
2, shall also be subject to the provisions of this Section 2. Notwithstanding the foregoing, and in addition thereto, each of Charter, Partisan, USVP and Camden (each a “Designating Party”) shall not vote to remove any director designated
by any other Designating Party, except for bad faith or willful misconduct. 

  
 (b) Board Size. Effective upon the date hereof, the authorized size of the Board of Directors shall be eight (8). Notwithstanding
anything in this Section 2 to the contrary, the number of directors constituting the entire Board of Directors of the Company may not be increased above eight (8) without the prior written consent of the holders of at least a majority of the then
issued and outstanding shares of Series A Preferred Stock and Series B Preferred Stock voting as a single class. 
  
 (c) Designations by USVP, Charter, Partisan and Camden. Notwithstanding the provisions of Section 2(a)(ii) and 2(a)(iii), the right
of each of USVP, Charter, Partisan and Camden to designate a Board member shall terminate as to such designating party at the time such designating party holds less than 1,000,000 shares of the Preferred Stock. For purposes of this Section 2(c), the
following shares shall be aggregated: (i) with respect to Partisan, any shares of Preferred Stock held by Partisan, The Weldon Foundation, Inc., Carol J. Weldon and Karen C. Cassidy; or (ii) with respect to USVP, Charter, Partisan or Camden, any
shares of Preferred Stock transferred by such designating party to (x) any person or entity that owns at least a majority of the voting equity of such designating party, (y) any entity in which such designating party owns at least a majority of the
voting equity, or (z) any other person or entity, so long as such designating party maintains sole voting control of such shares; or (iii) with respect to USVP, Charter, Partisan or 

  

 3 

 
Camden, any shares of Preferred Stock held by a person who is, with respect to USVP, Charter, Partisan or Camden, as the case may be, (x) a general partner,
limited partner, retired partner, member or retired member of such entity, or (y) a family member of such individuals or a trust for the benefit of such individuals or the individual’s family members, or (z) an affiliate of such entity (an
“affiliate” of a person is a second person directly or indirectly, through one or more intermediaries, controlling, controlled by or under common control with that first person). In addition, shares held by USVP VIII Affiliates, L.P., USVP
Entrepreneur Partners VIII-A, L.P., and USVP Entrepreneur Partners VIII-A, L.P. shall be aggregated with those of USVP for purposes of this Section 2(c). 
  
 (d) Observer Rights. For as long as Karen J. Cassidy continues to hold at least fifty percent (50%) of the total shares of stock of
the Company originally issued to her, Ms. Cassidy (hereinafter referred to as the “Observer”) shall be entitled to notice of, to attend and to any documentation distributed to members of the Board of Directors, during or after, all
meetings (including any action to be taken by written consent) of the Board of Directors and all committees thereof; provided, however, that the Company reserves the right to withhold any information and to exclude the Observer from any
meeting or portion thereof (so long as the Company notifies the Observer of such withholding and of any action taken by the Board of Directors as a result of such meeting) if access to such information or attendance at such meeting would, (a) in the
judgment of the Company’s outside counsel, adversely affect the attorney-client privilege between the Company and its counsel or cause the Board of Directors to breach its fiduciary duties, (b) in the good faith determination of the Board of
Directors, result in the disclosure of proprietary information regarding the Company’s intellectual property rights, the disclosure of which would have an adverse effect on the Company or (c) in the good faith determination of the Board of
Directors, involve a conflict of interest. The Company will use its commercially reasonable efforts to ensure that any withholding of information or any restriction on attendance is strictly limited only to the extent necessary set forth in the
preceding sentence. The Observer shall not be (y) permitted to vote at any meeting of the Board of Directors, or (z) counted for purposes of determining whether there is sufficient quorum for the Board of Directors to conduct its business. The
Observer shall hold all information received pursuant to this Agreement in the strictest confidence and shall not disclose the same to any third party (except Partisan’s agents and representatives, including Norman R. Weldon) nor use the same
for any purpose other than evaluating her investment in the Company. 
  
 3. Additional Parties to the Agreement. 
  
 (a) In connection with any sale, transfer, succession or assignment by any Stockholder subsequent to the date of this Agreement, other than by virtue of a sale to the public (pursuant to a registered public offering
or a transaction under Rule 144 of the Act), the Company and each of the Stockholders shall require such purchaser, transferee, successor or assignee,, as a condition of such sale, transfer, succession or assignment, to agree in writing to be bound
by all the terms and conditions of this Agreement. Notwithstanding anything in this Agreement to the contrary, this Agreement may be amended by the Company without the consent of the Stockholders to include each such purchaser, transferee, successor
or assignee as a party hereto. Upon such purchaser, transferee, successor or assignee executing and delivering an additional counterpart signature page to 

  

 4 

 
this Agreement, such purchaser, transferee, successor or assignee shall be deemed to be a “Stockholder” for all purposes under this Agreement. Upon
any person becoming a party to this Agreement as a Stockholder, other than those persons who are original signatories to this Agreement, the Company shall forthwith notify all Stockholders of the name and address of such additional parties to this
Agreement. 
  
 (b) Notwithstanding anything in
this Agreement to the contrary, this Agreement may be amended by the Company without the consent of the Stockholders to include any holder of the Company’s capital stock as a party hereto and which holder, upon executing and delivering an
additional counterpart signature page to this Agreement, shall be deemed to be a “Stockholder” for all purposes under this Agreement. 
  
 4. Company Obligation. The Company shall take all reasonable steps to assure compliance with the provisions of this Agreement. 
  
 5. Termination. This Agreement shall terminate upon the earliest to
occur of (a) a Qualified Public Offering (as defined in Article IV, Section 2(b)(i) of the Company’s Certificate of Incorporation), (b) the merger or consolidation of the Company with or into any other corporation or entity that results in all
Series A Preferred Stock and Series B Preferred Stock being converted into Common Stock (unless stockholders of the Company immediately prior to such transaction are holders of at least a majority of the voting securities of the surviving or
acquiring corporation thereafter, and for the purposes of this calculation, voting securities of the surviving or acquiring corporation which any stockholder of the corporation owned immediately prior to such merger or consolidation as stockholders
of another party to the transaction shall be disregarded) or (c) when less than 1,000,000 shares of Preferred Stock (excluding Conversion Stock) are outstanding. 
  
 6. Successors in Interest. The provisions of this Agreement shall be binding upon the successors in interest to any
of the Shares, except as to Shares sold to the public (pursuant to a registered public offering or a transaction under Rule 144 of the Act). The Company shall not permit the transfer of any of the Shares on its books or issue a new certificate
representing any of the Shares unless and until the person to whom such security is to be sold or transferred shall have executed a written agreement, substantially in the form of this Agreement, pursuant to which such person becomes a party to this
Agreement and agrees to be bound by all the provisions hereof as if such person were a Stockholder, as defined herein; provided, however, that nothing in this Agreement shall in any way limit the ability of each Stockholder to sell any
or all Shares to the public (pursuant to a registered public offering or a transaction under Rule 144 of the Act), and any Shares so distributed shall not be subject to this Agreement. 
  
 7. Inscription on Share Certificates. 
  
 (a) Each certificate representing any of the Shares shall be marked by the Company with a legend reading as
follows: 
  
 THE SHARES REPRESENTED HEREBY ARE SUBJECT TO A
VOTING AGREEMENT (A COPY OF WHICH MAY BE OBTAINED 

  

 5 

 
FROM THE ISSUER). ANY PERSON ACCEPTING ANY INTEREST IN SUCH SHARES SHALL BE DEEMED TO AGREE TO AND SHALL BECOME BOUND BY ALL OF THE PROVISIONS OF SUCH VOTING
AGREEMENT. 
  
 Each Stockholder and assignee of a Stockholder agrees to submit
promptly to the Company all certificates evidencing any shares of capital stock of the Company owned by him/her/it of record or beneficially, directly or indirectly, in order that the Company may endorse the foregoing legend on such certificates.
The Company agrees to endorse the foregoing legend on all certificates evidencing any shares of its capital stock held by any Stockholder or assignee of a Stockholder whether now outstanding or issued hereafter. 
  
 (b) The Company agrees that, during the term of this
Agreement, it will not remove, and will not permit to be removed (upon registration of transfer, reissuance or otherwise), the legend from any such certificate and will place or cause to be placed the legend on any new certificate issued to
represent Shares theretofore represented by a certificate carrying the legend. 
  
 8. Notices. All notices and other communications required or permitted hereunder shall be in writing and, except as otherwise noted herein, shall be deemed effectively given (i) upon personal delivery, (ii)
upon delivery by an internationally recognized courier (such as Fedex or DHL), (iii) when sent by confirmed telex or facsimile, if sent during normal business hours of the recipient; if not sent during normal business hours of the recipient, then on
the next business day, or (iv) five (5) days after having been sent by registered or certified mail, postage prepaid; addressed: (a) if to the Company, to it at 6033 Schumacher Park Drive, West Chester, Ohio 45069, Attention: President (or at such
other address as the Company shall have furnished to the Stockholders in writing), and (b) if to a Stockholder, to such Stockholder at the latest address of such Stockholder set forth on the Company’s records. 
  
 9. Validity and Severability; Amendments. 
  
 (a) Each Stockholder represents and warrants that (a) such
Stockholder now owns its Shares free and clear of liens or encumbrances and (b) such Stockholder has full power and capacity to execute, deliver and perform this Agreement, which has been duly executed and delivered by, and evidences the valid and
binding obligation of, such Stockholder enforceable in accordance with its terms. The Shares, as of the date hereof, are not subject to a proxy, voting agreement or other obligation, restriction or agreement affecting the validity of this Agreement.

  
 (b) If any provision of this Agreement is
held to be unenforceable under applicable law, it shall be interpreted, to the extent possible, to enhance its enforceability in order to achieve the intent of the parties to this Agreement. But if no feasible construction would save the provision,
the parties agree to renegotiate such provision in good faith. In the event the parties cannot reach a mutually agreeable and enforceable replacement for such provision, its invalidity, illegality or unenforceability shall not affect any other
provision of this Agreement; rather this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been 

  

 6 

 
contained herein; provided, however, no such severability shall be effective if it materially changes the economic benefit of this Agreement to
any party. The invalidity of any provision of this Agreement as applied to certain circumstances shall not affect the validity or enforceability of such provision as applied to other circumstances or any other provisions of this Agreement.

  
 (c) Subject to Section 3 hereof, this
Agreement may be amended only in writing upon the concurrence of: (i) with respect to Section 2(a)(i) hereof, the holders of a majority in interest of the then issued and outstanding shares of Common Stock; (ii) with respect to Sections 2(a)(ii),
2(a)(iii), 2(b) and 2(c) hereof, the holders of (A) 66-2/3% in interest of the then issued and outstanding shares of Series A Preferred Stock and (B) a majority in interest of the then issued and outstanding shares of Series B Preferred Stock,
voting separately (provided that the provisions with respect to designations of USVP, Charter, Partisan and Camden may only be amended by such designating party); and (iii) with respect to all other provisions of this Agreement, the holders of (x)
66-2/3% in interest of the then issued and outstanding shares of Series A Preferred Stock and (y) a majority in interest of the then issued and outstanding shares of Series B Preferred Stock, voting separately and (z) the holders of a majority in
interest of the then issued and outstanding shares of Common Stock, voting as a single class. 
  
 10. Governing Law. This Agreement shall be governed by and construed by the laws of the State of Delaware as applied to contracts between Delaware residents entered into and to be performed entirely within the
State of Delaware. 
  
 11. Counterparts. This Agreement may
be executed in two (2) or more counterparts each of which shall be deemed an original, but all of which, when taken together, shall constitute one and the same instrument. 
  
 12. Further Action. If and whenever any Shares are sold, the selling stockholders or their personal representatives
shall do all things and execute and deliver all documents and make all transfers, and cause any transferee of such Shares to do all things and execute and deliver all documents, as may be necessary to consummate such sale consistent with this
Agreement. 
  
 13. Specific Performance. The parties hereto
hereby declare that it is impossible to measure in money the damages which will accrue to a party hereto or to its heirs, personal representatives or assigns by reason of a failure to perform any of the obligations under this Agreement, and agree
that the terms of this Agreement shall be specifically enforceable. If any party hereto or its heirs, personal representatives or assigns institutes any action or proceeding to specifically enforce the provisions hereof, any person against whom such
action or proceeding is brought hereby waives the claim or defense therein that such party or such personal representative has an adequate remedy at law, and such person shall not offer in any such action or proceeding the claim or defense that such
remedy at law exists. 
  
 14. Waiver. No waivers of any
breach of this Agreement extended by any party to any other party shall be construed as a waiver of any rights or remedies of any other party or with respect to any subsequent breach. 
  

 7 

 15. Entire Agreement. This Agreement, along with the Purchase Agreement, each of the Exhibits
thereto and the other documents delivered pursuant thereto, constitute the full and entire understanding and agreement between the parties with regard to the subject matter hereof and thereof, and supersede all prior agreements and undertakings,
written and oral (including, without limitation, the Old Agreement), with respect to the subject matter hereof and thereof. 
  
 16. Descriptive Headings and Construction. The descriptive headings herein have been inserted for convenience only and shall not be deemed to limit
or otherwise affect the construction of any provisions hereof. A reference herein to any Section shall be deemed to include a reference to every subsection thereof. All pronouns contained herein, and any variations thereof, shall be deemed to refer
to the masculine, feminine or neuter, singular or plural, as to the identity of the parties hereto may require. 
  
 17. Further Assurances. Each of the parties hereto shall execute and deliver such instruments and take such other actions as the other parties may
reasonably request in order to carry out the intent of this Agreement. 
  
 18. Delays or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power
or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement,
or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or
otherwise afforded to any party, shall be cumulative and not alternative. 
  
 [remainder of page intentionally left blank] 
  

 8 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Voting Agreement on the day and
year first set forth above. 
  

			
	“COMPANY”
	
	 ATRICURE, INC.

		
	 By:
	 	 

	 Name:
	 	 Michael D. Hooven

	 Title:
	 	 President

  
 Signature Page
to Amended Voting Agreement 
  

			
	“PREFERRED STOCKHOLDERS”
	
	 U.S. VENTURE PARTNERS VIII, L.P.
 USVP VIII AFFILIATES FUND, L.P.
 USVP ENTREPRENEUR PARTNERS VIII-A, L.P.
 USVP ENTREPRENEUR PARTNERS VIII-B, L.P.
 By Presidio Management Group VIII, L.L.C.,
 The General Partner of Each

		
	By:	 	 

	 	 	 Michael P. Maher
 Attorney-In-Fact

	
	 CHARTER VENTURES IV, L.P.

		
	 By:
	 	 Charter Ventures IV Partners, LLC,

	 Its:
	 	 General Partner

		
	 By:
	 	 

	 	 	 A. Barr Dolan
 Managing Member

	
	 CHARTER ENTREPRENEURS FUND IV, L.P.

		
	 By:
	 	 Charter Ventures IV Partners, LLC,

	 Its:
	 	 General Partner

		
	 By:
	 	 

	 	 	 A. Barr Dolan
 Managing Member

  
 Signature Page
to Amended Voting Agreement 
  

			
	 CHARTER ADVISORS FUND IV, L.P.

		
	 By:
	 	 Charter Ventures IV Partners, LLC,

	 Its:
	 	 General Partner

		
	By:	 	 

	 	 	 A. Barr Dolan
 Managing Director

	
	 

	
	 PARTISAN MANAGEMENT GROUP, INC.

		
	 By:
	 	 

	 Name:
	 	 Karen J. Cassidy

	 Title:
	 	 Managing Director

	
	 THE WELDON FOUNDATION, INC.

		
	 By:
	 	 

	 Name:
	 	 Norman R. Weldon

	 Title:
	 	 President

	
	 CAMDEN PARTNERS STRATEGIC FUND II A, L.P.
 CAMDEN PARTNERS STRATEGIC FUND II B, L.P.

		
	 By:
	 	 Camden Partners Strategic II, LLC,

	 Its:
	 	 General Partner

		
	 By:
	 	 

	 Name:
	 	 Richard M. Johnston

	 Title:
	 	 Managing Member

  
 Signature Page
to Amended Voting Agreement 
  

			
	FOUNDATION MEDICAL PARTNERS, L.P.
		
	By:	 	Foundation Medical Managers, LLC
	Its:	 	General Partner
		
	By:	 	 

	 	 	 Lee R. Wrubel, M.D.

	 	 	 Managing Member

	
	 

	 UTAKO K. HUDSON

	
	 

	 CAROL J. WELDON

	
	 

	 FRANK M. FISCHER

	
	 

	 KAREN J. CASSIDY

	
	 

	 DONALD C. HARRISON, M.D.

	
	 

	 LOWELL S. LIFSCHULTZ

	
	 

	CHRISTIAN L. MAZZOLA, AS TRUSTEE FOR THE CHRISTIAN L. MAZZOLA REVOCABLE TRUST DATED JULY 29, 1993
	
	 

	 RICHARD J. D’AUGUSTINE

  
 Signature Page
to Amended Voting Agreement 
  

									
				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 MERIDA A. D’AUGUSTINE

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 MICHAEL D. HOOVEN

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 KAREN P. ROBARDS

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 RAYMOND W. OGLE

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 WILLIAM P. SANTAMORE, Ph.D.

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 STEWART H. GREENFIELD

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 ROBERT A. KLINE

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	RANDALL WOLF, M.D. AND AMY STERNSTEIN, HUSBAND AND WIFE
				
	 	 	 	 	 	 	DUKE UNIVERSITY SPECIAL VENTURES FUND, INC.
				
	 

	 	 	 	By:	  	 

	 Neal Triplett, Assistant Director
	 	 	 	 Name:
	  	 David R. Shumate

	 	 	 	 	 	 	 Title:
	  	Vice President, Duke Management Company Authorized Agent
					
	 	 	 	 	 	 	 	  	Signature Page to Amended Voting Agreement

			
	GREENFIELD FAMILY, L.P.
		
	By:	 	 

	 Name:
	 	 
	 Title:
	 	 
	
	O STREET CORPORATION
		
	By:	 	 

	 Name:
	 	 Curtin Winsor

	 Title:
	 	 President

	
	 

	 ELIZABETH H. LIFSCHULTZ

  
 Signature Page
to Amended Voting Agreement 
  

									
	 	 	 	 	 	 	 terms of the Company’s Certificate of Incorporation and Bylaws, until the termination of this Agreement pursuant to
Section
 “COMMON STOCKHOLDERS”

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 PAUL A. BROOKE

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 JAMES A. CHALDEKAS

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 FREDERIC C. COLMAN

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 JAMES F. DANIELL, M.D.

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 JAMES E. DAVIS

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 JOSEPH H. DAVIS

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 ANN E. FISHER

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 JOHN G. FREUND

				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	LAWRENCE H. FUCHS AND BETTY C. FUCHS, HUSBAND AND WIFE
				
	 	 	 	 	 	 	 

	 	 	 	 	 	 	 ANNETTE M. GERDING

					
	 	 	 	 	 	 	 	 	Signature Page to Amended Voting Agreement

  

	
	
	 

	 DR. SYLVAN GOLDIN

	
	 

	 STEVEN L. HENDERSON

	
	 

	 BONNIE LEETMAA-LIVINGSTON         5/28/02

	
	 

	 THOMAS W. LUND

	
	 

	 JOHN B. MARTIN, JR.

	
	 

	 J. BARRY MCKERNAN, M.D.

	
	 

	 SANFORD S. OSHER, M.D.

	
	

            5/23/02
	 PHOTIOS PAULSON

	
	 

	 EDWARD H. PHILLIPS, M.D.

	
	 

	 LEONARD PINCHUK

	
	 

	 C. DANIEL SMITH, M.D.

  
 Signature Page
to Amended Voting Agreement 
  

	
	
	

	EBERHARD H. SPIES AND ERIKA A. SPIES, HUSBAND AND WIFE
	
	

	SUSAN SPIES
	
	

	NORMAN R. WELDON
	
	

	PATRICIA K. WOOLF
	
	

	THOMAS D. WELDON, AS CUSTODIAN FOR MATTHEW T. DODSON UNDER THE OHIO UNIFORM TRANSFERS TO MINORS ACT
	
	

	THOMAS D. WELDON, AS CUSTODIAN FOR ERIC R. DODSON UNDER THE OHIO UNIFORM TRANSFERS TO MINORS ACT
	
	

	THOMAS D. WELDON, AS CUSTODIAN FOR CHRISTOPHER R. WELDON UNDER THE OHIO UNIFORM TRANSFERS TO MINORS ACT
	
	

	THOMAS D. WELDON, AS CUSTODIAN FOR ANDREW M. DODSON UNDER THE OHIO UNIFORM TRANSFERS TO MINORS ACT
	
	 
	R. DAVID WELDON

  
 Signature Page
to Amended Voting Agreement 

	
	
	

	CYNTHLA M. WELDON, AS CUSTODIAN FOR MICHAEL J. WELDON UNDER THE OHIO UNIFORM TRANSFERS TO MINORS ACT
	
	

	DAVID J. WELDON
	
	

	MARIJKE L. WELDON

  
 Signature Page
to Amended Voting AgreementSpecimen of warrant certificate issued to Series B preferred shareholders

 EXHIBIT 4.5 
  
 NEITHER THIS WARRANT, NOR THE CAPITAL STOCK TO BE ISSUED UPON EXERCISE HEREOF (NOR THE COMMON STOCK TO BE ISSUED UPON CONVERSION OF
PREFERRED STOCK), HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“1933 SECURITIES ACT”), OR QUALIFIED OR REGISTERED UNDER CALIFORNIA OR OTHER APPLICABLE SECURITIES LAWS (“STATE SECURITIES
LAWS”), AND THIS WARRANT HAS BEEN, AND THE COMMON STOCK OR PREFERRED STOCK (AND THE COMMON STOCK TO BE ISSUED UPON CONVERSION OF SUCH PREFERRED STOCK) TO BE ISSUED UPON EXERCISE HEREOF WILL BE, ACQUIRED FOR INVESTMENT AND NOT WITH A
VIEW TO, OR FOR RESALE IN CONNECTION WITH, ANY DISTRIBUTION THEREOF. NO SUCH SALE OR OTHER DISPOSITION MAY BE MADE WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE 1933 SECURITIES ACT AND COMPLIANCE WITH THE APPLICABLE STATE SECURITIES LAWS OR
AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE ISSUER AND ITS COUNSEL, THAT SAID REGISTRATION IS NOT REQUIRED UNDER THE 1933 SECURITIES ACT AND THAT APPLICABLE STATE SECURITIES LAWS HAVE BEEN COMPLIED WITH. 
  
 Issued as of April 22, 2002 
  
 ATRICURE, INC. 
  
 WARRANT 
  
 This certifies that, for value received,
                     (“Purchaser”), whose address for notice is as listed on the signature page hereto, or any party
to whom this Warrant is assigned in compliance with the terms hereof (Purchaser and any such assignee being hereinafter sometimes referenced as “Holder”), is entitled to subscribe for and purchase shares of the capital stock
of Atricure, Inc., a Delaware corporation (the “Company”), determined as set forth below. Such right shall terminate upon the earlier of (i) one year after the date of the consummation of the initial public offering by
Company of its Common Stock to the public generally pursuant to a registration statement in an underwritten offering or (ii) the seventh (7th) anniversary after the issue date hereof, after which time, this Warrant shall expire. 
  
 This Warrant is one of a duly authorized series of Warrants of the Company (which Warrants are identical except for the variations necessary to express
the name of the Holder, number, and Aggregate Price of each Warrant). The purchase price of this Warrant shall be Ninety Two Thousand One Hundred Dollars ($92,100.00) plus interest accrued pursuant to the Note. Capitalized terms used but not
otherwise defined herein shall have the same meanings given such terms in the Note. 

 AtriCure, Inc. 
 Warrant

 Page 2 
  
 ARTICLE I 
 DEFINITIONS 
  
 1.1 “Aggregate Price” shall mean Ninety Two Thousand
One Hundred Dollars ($92,100.00) plus interest accrued pursuant to the Note. 
  
 1.2 “Change of Control Event” shall have the meaning set forth in the Note. 
  
 1.3 “Equity Financing” shall be the first offering of the Company’s equity that closes after the date of the original issue
of this Warrant and on or before the date which is six (6) months from the date hereof, with cash proceeds to the Company of not less than Three Million Dollars ($3,000,000) (excluding conversion of the Notes issued pursuant to the Subscription
Agreement and any other promissory notes issued by the Company) for payment of capital stock and shall exclude sales of capital stock to employees, officers, directors and consultants in connection with employee benefit plans and shall exclude
amounts received from the sale of debt instruments convertible into the capital stock until such time as such instruments are converted into capital stock. 
  
 1.4 “Financing Units” means units of the Company’s equity issued in the Equity
Financing. 
  
 1.5 “Maturity Date”
shall have the meaning set forth in the Note. 
  
 1.6
“Note” means the Convertible Promissory Note, dated an even date herewith, issued to Purchaser pursuant to the Subscription Agreement. 
  
 1.7 “Preferred Stock” shall mean shares of the Company’s Series A Stock or any other series or
class of preferred stock of the Company, including if applicable, the Financing Units. 
  
 1.8 “Series A Stock” shall mean shares of the Company’s Series A Preferred Stock. 
  
 1.9 “Subscription Agreement” shall mean the Subscription Agreement by and among the Company and the Purchaser and other purchasers
named therein, dated an even date herewith, under which this Warrant and the Note are issued. 
  
 1.10 “Warrant Price” shall mean, as adjusted herein: (i) in the case of an Equity Financing, the lowest per unit price of the
Financing Units sold in the Equity Financing; (ii) in the case of a Change of Control Event occurring prior to the date which is six (6) months from the date hereof, one dollar and fifty cents ($1.50) per share; and (iii) in the case of the Maturity
Date which occurs six (6) months after the date hereof without the Company having an Equity Financing or Change of Control Event on or prior to such date, sixty-three cents ($0.63) per share. 

 AtriCure, Inc. 
 Warrant

 Page 3 
  
 1.11 “Warrant Stock” shall mean the Company’s Common Stock, Series A Stock or Financing Units. In the event of an Equity
Financing, the Warrant Stock shall be Financing Units; in the event of a Change of Control Event prior to the date which is six (6) months from the date hereof, the Warrant Stock shall be the Company’s Common Stock; and in the event the
Maturity Date occurs on the date which is six (6) months from the date hereof and an Equity Financing or Change of Control Event has not occurred on or prior to such date, the Warrant Stock shall be Series A Stock. 
  
 ARTICLE II 
 EXERCISE AND PAYMENT 
  
 2.1 Cash Exercise. The purchase rights represented by this Warrant may be exercised by Holder, in whole or in part, by the surrender of this Warrant at the principal office of the Company, located at the
address set forth on the signature page hereof, accompanied by the form of Notice of Cash Exercise attached hereto as Exhibit “A-l,” and by the payment to the Company, by cash or by certified, cashier’s or other check acceptable to
the Company, of an amount equal to the aggregate Warrant Price of the shares of Warrant Stock being purchased. 
  
 2.2 Net Issue Exercise. In lieu of exercising this Warrant pursuant to Section 2.1, Holder may elect to receive shares of Warrant Stock
equal to the value of this Warrant determined in the manner described below (or of any portion thereof remaining unexercised) by surrender of this Warrant at the principal office of the Company together with the form of Notice of Cashless Exercise
attached hereto as Exhibit “A-2,” in which event the Company shall issue to Holder a number of shares of the Company’s Warrant Stock computed using the following formula: 
  
 X=Y(A-B) 
           A 
  

									
	Where  	  	X	  	 	  	=    	  	the number of shares of Warrant Stock to be issued to Holder (on the date of such calculation).
					
	 	  	Y	  	 	  	=	  	the number of shares of Warrant Stock purchasable under this Warrant (at the date of such calculation).
					
	 	  	A	  	 	  	=	  	the fair market value of one share of the Company’s Warrant Stock (at the date of such calculation).
					
	 	  	B	  	 	  	=	  	Warrant Price (as adjusted to the date of such calculation).

  
 2.3 Fair Market
Value. For purposes of this Article II, fair market value of one unit or share of the Company’s Warrant Stock shall mean the fair market value of that number of 

 AtriCure, Inc. 
 Warrant

 Page 4 
  
 shares of Common Stock which are then receivable upon conversion of one share of Warrant Stock, with the valuation of such Common Stock being as set forth below: 
  
 (i) The average of the closing bid and asked prices of the Common Stock
quoted in the Over-The-Counter Market Summary, the last reported sale price of the Common Stock or the closing price quoted on the Nasdaq National Market System (“NMS”) or on any exchange on which the Common Stock is listed,
whichever is applicable, as published in the Western Edition of The Wall Street Journal for the ten (10) trading days prior to the date of determination of fair market value, or if the Company’s stock has been listed or on the NMS for fewer
than ten (10) days, such fewer number of days; or 
  
 (ii) If the
Common Stock is not traded Over-The-Counter, on the NMS or on an exchange, the per share fair market value of the Warrant Stock shall be as determined by mutual agreement of the Company and the Holder; provided, however that if such agreement
cannot be reached within twenty (20) calendar days, such value shall be determined by an independent appraiser appointed in good faith by the Company’s Board of Directors. The cost of such appraisal shall be borne by the Company. 
  
 2.4 Automatic Conversion. If the Company’s Preferred Stock
has been automatically converted into Common Stock pursuant to the terms and conditions of the Preferred Stock, this Warrant shall automatically convert into a right to purchase Common Stock, pursuant to the formulas set forth in Section 2.3 above,
and the number of shares of Common Stock to which the Holder shall be entitled to purchase shall be multiplied by that number of shares of Common Stock which were received upon conversion of one share of Preferred Stock at the time of such automatic
conversion. 
  
 2.5 Stock Certificates. In the event
of any exercise of the rights represented by this Warrant, certificates for the shares of Warrant Stock so purchased shall be delivered to Holder within a reasonable time and, unless this Warrant has been fully exercised or has expired, a new
Warrant representing the remaining unexercised portion of this Warrant shall also be issued to Holder at such time. Notwithstanding the date of the delivery of the certificate(s) for the Warrant Stock, the person in whose name the certificate(s) for
such Warrant Stock are to be issued shall be deemed to have become a stockholder of record on the next succeeding day on which the transfer books are open after the date of the appropriate Notice of Exercise is received by the Company. 

 
 2.6 Stock Fully Paid; Reservation of Shares. The Company
covenants and agrees that all Warrant Stock which may be issued upon the exercise of the rights represented by this Warrant (and all Common Stock receivable upon conversion of Preferred Stock issued upon exercise of this Warrant) will, upon
issuance, be fully paid and nonassessable and free from all taxes, liens and charges with respect to the issue thereof (excluding taxes based on the income of Holder). The Company further covenants and agrees that during the period within which the
rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved for issuance a sufficient number of shares of its Preferred Stock (and 

 
AtriCure, Inc. 
 Warrant 
 Page 5 
  
 sufficient shares of Common Stock for conversion thereof) or other securities as would be required upon the full exercise of the rights represented by this Warrant (including conversion of all Preferred Stock issuable hereunder).

  
 2.7 Fractional Shares. No fractional
share of Warrant Stock will be issued in connection with any exercise hereof; in lieu of a fractional share upon complete exercise hereof, the Company shall round up to the next full share. 
  
 2.8 Automatic Exercise. To the extent this Warrant is
not previously exercised, and if the fair market value of one share of the Company’s Warrant Stock is greater than the Warrant Price, as adjusted, this Warrant shall be deemed automatically exercised in accordance with Section 2.2 hereof (even
if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the Company’s Warrant Stock upon such expiration shall be the fair market value determined pursuant to Section
2.3 above. To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 2.8, the Company agrees to notify Holder within a reasonable period of time of the number of shares of the Company’s Warrant
Stock, if any, Holder is to receive by reason of such automatic exercise. 
  
 2.9 Issuance of Substitute Warrant. Within thirty (30) calendar days after the first to occur of (i) an Equity Financing, (ii) Change of Control Event or (iii) the date which is six (6) months
from the date hereof, the Company shall issue to the Holder a new warrant of like form, tenor and effect, as a substitute for this Warrant, which sets forth the class of Warrant Stock for which this Warrant is exercisable and the number of shares of
Warrant Stock subject to this Warrant. Upon the issuance of such substitute warrant, this Warrant shall be of no further force or effect, and shall be surrendered by Holder to the Company and cancelled. 
  
 ARTICLE III 
 CERTAIN ADJUSTMENTS OF NUMBER OF SHARES PURCHASABLE AND 
 WARRANT
PRICE 
  
 The number and kind of securities purchasable
upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the happening of certain events, as follows: 
  
 3.1 Reclassification, Consolidation or Merger. In case of: (i) any reclassification or change of outstanding securities issuable upon
exercise of this Warrant; (ii) any consolidation or merger of the Company with or into another corporation (other than a merger with another corporation in which the Company is a continuing corporation and which does not result in any
reclassification, change or exchange of outstanding securities issuable upon exercise of this Warrant); or (iii) any sale or transfer to another corporation of all, or substantially all, of the property of the Company, then, and in each such event,
the Company or such successor or purchasing corporation, as the case may be, shall execute a new Warrant of like form, tenor and 

 
AtriCure, Inc. 
 Warrant 
 Page 6 
  
 effect and which will provide that Holder shall have the right to exercise such new Warrant and purchase upon such exercise, in lieu of each share of Preferred Stock theretofore issuable upon exercise of this Warrant, the kind and amount of
securities, money and property receivable upon such reclassification, change, consolidation, merger, sale or transfer by a holder of one share of Warrant Stock issuable upon exercise of this Warrant had this Warrant been exercised immediately prior
to such reclassification, change, consolidation, merger, sale or transfer. Such new Warrant shall be as nearly equivalent in all substantive respects as practicable to this Warrant and the adjustments provided in this Article III and the provisions
of this Section 3.1, shall similarly apply to successive reclassifications, changes, consolidations, mergers, sales and transfers. 
  
 3.2 Subdivision or Combination of Shares. If the Company shall at any time while this Warrant remains outstanding and less than fully
exercised: (i) divide its Warrant Stock, the Warrant Price shall be proportionately reduced; or (ii) shall combine shares of its Warrant Stock, the Warrant Price shall be proportionately increased. 
  
 3.3 Other Action Affecting Warrant Stock. If the Company
takes any action affecting its Warrant Stock after the date hereof (including dividends and distributions), other than an action described in any of Sections 3.1 and 3.2 hereof, which would have an adverse effect upon Holder’s rights hereunder,
the Warrant Price shall be adjusted downward in such manner and at such time as the Board of Directors of the Company shall in good faith determine to be equitable under the circumstances. 
  
 3.4 Time of Adjustments to the Warrant Price. All
adjustments to the Warrant Price and the number of shares purchasable hereunder, unless otherwise specified herein, shall be effective as of the earliest of: 
  
 (i) the date of issue of the security causing the adjustment; 
  
 (ii) the date of sale of the security causing the adjustment; 
  
 (iii) the effective date of a division or combination of shares; and 
  
 (iv) the record date of any action of holders of any class of the
Company’s capital stock taken for the purpose of entitling shareholders to receive a distribution or dividend payable in equity securities, provided that such division, combination, distribution or dividend actually occurs. 
  
 3.5 Notice of Adjustments. In each case of an adjustment
in the Warrant Price and the number of shares purchasable hereunder, the Company, at its expense, shall cause the Chief Financial Officer of the Company to compute such adjustment and prepare a certificate setting forth such adjustment and showing
in detail the facts upon which such adjustment is based. The Company shall promptly mail a copy of each such certificate to Holder pursuant to Section 6.8 hereof. 

 AtriCure, Inc. 
 Warrant

 Page 7 
  
 3.6 Duration of Adjusted Warrant Price. Following each adjustment of the Warrant Price, such adjusted Warrant Price shall remain in
effect until a further adjustment of the Warrant Price. 
  
 3.7 Adjustments to Conversion Rate. The Holder upon purchase of Preferred Stock pursuant to this Warrant, shall be entitled to all adjustments to Conversion Price made available to holders of the Preferred Stock
from and after the first date of first issue of a share of Preferred Stock by the Company. 
  
 ARTICLE IV 
 TRANSFER, EXCHANGE AND LOSS 
  
 4.1 Transfer. This Warrant is transferable on the books
of the Company at its principal office by the registered Holder hereof upon surrender of this Warrant properly endorsed, subject to compliance with federal and state securities laws. The Company shall issue and deliver to the transferee a new
Warrant or Warrants representing the Warrants so transferred. Upon any partial transfer, the Company will issue and deliver to Holder a new Warrant or Warrants with respect to the Warrants not so transferred. Notwithstanding the foregoing, Holder
shall not be entitled to transfer a number of shares or an interest in this Warrant representing less than five percent (5%) of the aggregate shares initially covered by this Warrant (as presently constituted, with appropriate adjustment being made
in the event of stock splits, combinations, reorganizations and the like occurring after the issue date hereof). Any transferee shall be subject to the same restrictions on transfer with respect to this Warrant as the Purchaser. 

 
 4.2 Securities Laws. Upon any issuance of shares of
Warrant Stock upon exercise of this Warrant (or of Common Stock upon conversion of Preferred Stock issued upon exercise of this Warrant), it shall be the Company’s responsibility to comply with the requirements of: (i) the Securities Act of
1933; (ii) the Securities Exchange Act of 1934, as amended; (iii) any applicable listing requirements of any national securities exchange; (iv) any state securities regulation or “Blue Sky” laws; and (v) requirements under any other law or
regulation applicable to the issuance or transfer of such shares. In connection with the issuance to Purchaser of this Warrant, Purchaser agrees to execute an investment intent letter or purchase agreement in such form as reasonably requested by the
Company and its counsel and as may be required to comply with federal and applicable state securities laws. If required by the Company, in connection with each issuance of shares of Warrant Stock upon exercise of this Warrant, the Holder will give:
(A) assurances in writing, satisfactory to the Company, that such shares are not being purchased with a view to the distribution thereof in violation of applicable laws, (B) sufficient information, in writing, to enable the Company to rely on
exemptions from the registration or qualification requirements of applicable laws, if available, with respect to such exercise, and (C) its cooperation to the Company in connection with such compliance. 
  
 4.3 Exchange. This Warrant is exchangeable at the
principal office of the Company for Warrants which represent, in the aggregate, the Holder’s rights to purchase the number of 
  
  

 AtriCure, Inc. 
 Warrant

 Page 8 
  
 shares of Warrant Stock covered by this Warrant at the Warrant Price; each new Warrant to represent the right to purchase the number of shares of Warrant Stock covered by this Warrant as Holder shall designate at the
time of such exchange. Each new Warrant shall be identical in form and content to this Warrant, except for appropriate changes in the number of shares of Warrant Stock covered thereby, the percentage stated in Section 4.1 above, and any other
changes which are necessary in order to prevent the Warrant exchange from changing the respective rights and obligations of the Company and the Holder as they existed immediately prior to such exchange. 
  
 4.4 Loss or Mutilation. Upon receipt by the Company of
evidence satisfactory to it of the ownership of, and the loss, theft, destruction or mutilation of, this Warrant and (in the case of loss, theft, or destruction) of indemnity satisfactory to it, and (in the case of mutilation) upon surrender and
cancellation hereof, the Company will execute and deliver in lieu hereof a new Warrant. 
  
 ARTICLE V 
 HOLDER RIGHTS 
  
 5.1 No Shareholder Rights Until Exercise. No Holder hereof, solely by virtue hereof,
shall be entitled to any rights as a shareholder of the Company. Holder shall have all rights of a shareholder with respect to securities purchased upon exercise hereof as of the date set forth in Section 2, including but not limited to,
antidilution protection, liquidation preferences, registration rights, and information rights, if applicable. 
  
 ARTICLE VI 
 MISCELLANEOUS 
  
 6.1 Governmental Approvals. The Company will from time
to time take all action which may be necessary to obtain and keep effective any and all permits, consents and approvals of governmental agencies and authorities and securities acts filings under federal and state laws, which may be or become
requisite in connection with the issuance, sale, and delivery of this Warrant, and the issuance, sale and delivery of the Warrant Stock or other securities or property issuable or deliverable upon exercise of this Warrant. 
  
 6.2 GOVERNING LAWS. IT IS THE INTENTION OF THE PARTIES
HERETO THAT EXCEPT AS SET FORTH BELOW, THE INTERNAL LAWS OF THE STATE OF DELAWARE, U.S.A. (IRRESPECTIVE OF ITS CHOICE OF LAW PRINCIPLES) SHALL GOVERN THE VALIDITY OF THIS WARRANT, THE CONSTRUCTION OF ITS TERMS, AND THE INTERPRETATION AND ENFORCEMENT
OF THE RIGHTS AND DUTIES OF THE PARTIES HERETO. 
  
  

 AtriCure, Inc. 
 Warrant

 Page 9 
  
 6.3 Binding Upon Successors and Assigns. Subject to, and unless otherwise provided in, this Warrant, each and all of the covenants, terms,
provisions, and agreements contained herein shall be binding upon, and inure to the benefit of the permitted successors, executors, heirs, representatives, administrators and assigns of the parties hereto. 
  
 6.4 Severability. If any one or more provisions of this
Warrant, or the application thereof, shall for any reason and to any extent be invalid or unenforceable, the remainder of this Warrant and the application of such provisions to other persons or circumstances shall be interpreted so as best to
reasonably effect the intent of the parties hereto. The parties further agree to replace any such void or unenforceable provisions of this Warrant with valid and enforceable provisions which will achieve, to the extent possible, the economic,
business and other purposes of the void or unenforceable provisions. 
  
 6.5 Default, Amendment and Waivers. This Warrant may be amended upon the written consent of the Company and the holders in the aggregate of the right to purchase a majority of the number of unexercised
shares of Warrant Stock covered by the Warrant initially issued by the Company pursuant to the Subscription Agreement. The waiver by a party of any breach hereof for default in payment of any amount due hereunder or default in the performance hereof
shall not be deemed to constitute a waiver of any other default or any succeeding breach or default. The failure to cure any breach of any term of this Warrant within ten (10) days of written notice thereof shall constitute an event of default under
this Warrant. 
  
 6.6 No Waiver. The failure
of any party to enforce any of the provisions hereof shall not be construed to be a waiver of the right of such party thereafter to enforce such provisions. 
  
 6.7 Attorneys’ Fees. Should suit be brought to enforce or interpret any part of this Warrant, the
prevailing party shall be entitled to recover, as an element of the costs of suit and not as damages, reasonable attorneys’ fees to be fixed by the court (including without limitation, costs, expenses and fees on any appeal). The prevailing
party shall be the party entitled to recover its costs of suit, regardless of whether such suit proceeds to final judgment. A party not entitled to recover its costs shall not be entitled to recover attorneys’ fees. No sum for attorneys’
fees shall be counted in calculating the amount of a judgment for purposes of determining if a party is entitled to recover costs or attorneys’ fees. 
  
 6.8 Notices. Whenever any party hereto desires or is required to give any notice, demand, or request with
respect to this Warrant, each such communication shall be in writing and shall be effective only if it is delivered by personal service or mailed, United States certified mail, postage prepaid, return receipt requested, addressed as set forth on the
signature page hereof. Such communications shall be effective when they are received by the addressee thereof; but if sent by certified mail in the manner set forth above, they shall be effective three (3) business days after being deposited in the
United States mail. Any party may change its address for such communications by giving notice thereof to the other party in conformity with this Section. 

 AtriCure, Inc. 
 Warrant

 Page 10 
  
 6.9 Time. Time is of the essence of this Warrant. 
  
 6.10 Construction of Agreement. A reference in this Warrant to any Section shall include a reference to every
Section the number of which begins with the number of the Section to which reference is specifically made (e.g., a reference to Section 3 shall include a reference to Sections 3.5 and 3.7). The titles and headings herein are for reference
purposes only and shall not in any manner affect the interpretation of this Warrant. 
  
 6.11 No Endorsement. Holder understands that no federal or state securities administrator has made any finding or determination relating to the fairness of investment in the Company or purchase of the
Warrant Stock hereunder and that no federal or state securities administrator has recommended or endorsed the offering of securities by the Company hereunder. 
  
 6.12 Pronouns. All pronouns and any variations thereof shall be deemed to refer to the masculine, feminine or
neuter, singular or plural, as the identity of the person, persons, entity or entities may require. 
  
 6.13 Further Assurances. Each party agrees to cooperate fully with the other parties and to execute such further instruments, documents and
agreements and to give such further written assurances, as may be reasonably requested by any other party to better evidence and reflect the transactions described herein and contemplated hereby, and to carry into effect the intents and purposes of
this Warrant. 
  

			
	ATRICURE, INC.
		
	By:	 	  

	Name:	 	 
	Title:	 	 
		
	Address:	 	6033 Schumacher Park Drive
	 	 	West Chester, Ohio 45069-4812

 AtriCure, Inc. 
 Warrant

 Page 11 
  

			
	HOLDER:
		
	By:	 	  

	Name:	 	  

	Title:	 	  

	Address:	 	  

	 	 	  

  
  

 AtriCure, Inc. 
 Warrant

 Page 12 
  
 EXHIBIT “A-1” 
  
 NOTICE OF EXERCISE OF WARRANT 
 BY CASH PAYMENT OF WARRANT PRICE 
  

	
	
	_____________________________
	(Date)

  

					
	 Atricure, Inc.
 6033 Schumacher Park Drive
 West Chester, Ohio 45069-4812
 Attention: President
	  	 Aggregate Price of Warrant
 Before
Exercise:
	 	$____________________
	  	 
			
	 	  	 Aggregate Price Being
 Exercised:
	 	$____________________
			
	 	  	Warrant Price per share:	 	$____________________
			
	 	  	 Number of Shares of
 Warrant Stock to be
Issued
 Under this Notice:
	 	  ____________________
			
	 	  	 Remainder Aggregate Price
 (if any) After
Issuance:
	 	  ____________________

  
 CASH EXERCISE

  
 Ladies and Gentlemen: 
  
 The undersigned registered Holder of the Warrant delivered herewith (the
“Warrant”), hereby irrevocably exercises such Warrant for, and purchases thereunder, shares of the
                                        
of Atricure, Inc., a Delaware corporation, as provided below. Capitalized terms used herein, unless otherwise defined herein, shall have the meanings given in the Warrant. 
  
 The portion of the Aggregate Price (as defined in the Warrant) to be applied toward the purchase of
                     Stock pursuant to this Notice of Exercise is
$                    , thereby leaving a remainder Aggregate Price (if any) equal to $
                    . Such exercise shall be pursuant to the cash exercise provisions of Section 2.1 of the Warrant. Therefore, Holder makes
payment with this Notice of Exercise by way of check payable to the Company in the amount of $                    . Such check is payment in
full under the Warrant for                      shares of
                     based upon the Warrant Price of
$                     per share, as currently in effect under the Warrant. 
  
  

 AtriCure, Inc. 
 Warrant

 Page 13 
  
 Holder requests that the certificates for the purchased shares of
                     be issued in the name of and delivered to
                    ,
                    , respectively. To the extent the foregoing exercise is for less than the full Aggregate Price of the Warrant, a
replacement Warrant representing the remainder of the Aggregate Price (and otherwise of like form, tenor and effect) shall be delivered to Holder along with the share certificate evidencing the
                     Stock issued in response to this Notice of Exercise. 
  

			
	HOLDER:
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 NOTE

  
 The execution to the foregoing Notice of Exercise must
exactly correspond to the name of the Holder as typed on Warrant. 
  
  

 AtriCure, Inc. 
 Warrant

 Page 14 
  
 EXHIBIT “A-2” 
  
 NOTICE OF EXERCISE OF WARRANT 
 PURSUANT TO NET ISSUE (“CASHLESS”) EXERCISE PROVISIONS

  

	
	
	_____________________________
	(Date)

  

					
	 Atricure, Inc.
 6033 Schumacher Park
Drive
 West Chester, Ohio 45069-4812
 Attention:
President
	  	 Aggregate Price of
 Warrant Before
Exercise:
	  	$____________________
	  	  
			
	 	  	 Aggregate Price Being
 Exercised:
	  	$____________________
			
	 	  	Warrant Price per share:	  	$____________________
			
	 	  	 Number of Shares of
 Warrant Stock to be
Issued
 Under this Notice:
	  	  ____________________
			
	 	  	 Remainder Aggregate
 Price (if any) After
 Issuance:
	  	  ____________________

  
 CASHLESS EXERCISE

  
 Ladies and Gentlemen: 
  
 The undersigned, registered Holder of the Warrant delivered herewith
(“Warrant”), hereby irrevocably exercises such Warrant for, and purchases thereunder, shares of the
                     of Atricure, Inc., a Delaware corporation, as provided below. Capitalized terms used herein, unless otherwise defined
herein, shall have the meanings given in the Warrant. 
  
 The
portion of the Aggregate Price (as defined in the Warrant) to be applied toward the purchase of                      Stock pursuant to this
Notice of Exercise is $                    , thereby leaving a remainder Aggregate Price (if any) equal to
$                    . Such exercise shall be pursuant to the net issue exercise provisions of Section 2.2 of the Warrant; therefore, Holder
makes no payment with this Notice of Exercise. The number of shares to be issued pursuant to this exercise shall be determined by reference to the formula in Section 2.2 of the Warrant which, by reference to Section 2.3, requires the use of the
current per share fair market value of the Company’s Common Stock. The current fair market value of one share of the 

 
AtriCure, Inc. 
 Warrant 
 Page 15 
  
 Company’s Common Stock shall be determined in the manner provided in Section 2.3, which amount has been determined or agreed to by Holder and the Company to be
$                    , which figure is acceptable to Holder for calculations of the number of shares of
                     issuable pursuant to this Notice of Exercise. 
  
 Holder requests that the certificates for the purchased shares of
                     be issued in the name of and delivered to
                    . To the extent the foregoing exercise is for less than the full Aggregate Price of the Warrant, a replacement Warrant
representing the remainder of the Aggregate Price (and otherwise of like form, tenor and effect) shall be delivered to Holder along with the share certificate evidencing the
                     Stock issued in response to this Notice of Exercise. 
  

			
	HOLDER:	 	 
		
	By:	 	  

	Name:	 	  

	Title:	 	  

  
 NOTE

  
 The execution to the foregoing Notice of Exercise must
exactly correspond to the name of the Holder as typed on Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]